Clinical Trial

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-08-28; most recent amendment 2026-07-20.
Status change: Recruiting → Active, Not Recruiting 2025-08-08
Trial Details
NCT Number NCT06021522
Lead Sponsor Emalex Biosciences Inc.
Conditions Tourette Syndrome
Enrollment 150 participants
Start Date 2023-08-16
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-22